$2.12
1.85%
Nasdaq, Sep 25, 04:00 pm EDT.
ISIN
CA00430K4028
Symbol
GRCE

Acasti Pharma Inc. Class A Target price 2026 - Analyst rating & recommendation

Acasti Pharma Inc. Class A Classifications & Recommendation

Buy
88%
Hold
13%

Acasti Pharma Inc. Class A Price Target

Target Price $6.12
Price $2.12
Potential
Number of Estimates 4
4 Analysts have issued a price target Acasti Pharma Inc. Class A 2027 . The average Acasti Pharma Inc. Class A target price is $6.12. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 8 analysts: 7 Analysts recommend Acasti Pharma Inc. Class A to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Acasti Pharma Inc. Class A stock has an average upside potential 2027 of . Most analysts recommend the Acasti Pharma Inc. Class A stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2027, 2028 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Mar '26 2027
Estimates
P/E negative
EV/Sales 6.05

4 Analysts have issued a Acasti Pharma Inc. Class A forecast for earnings per share. The average Acasti Pharma Inc. Class A EPS is

$-0.67
unlock
. This is
43.22% higher
unlock
than earnings per share in the financial year 2026. The highest EPS forecast is
$-0.55 53.39%
unlock
, the lowest is
$-0.78 33.90%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2028
$-0.57 14.93%
unlock
2029
$0.36 163.16%
unlock
2030
$1.58 338.89%
unlock
2031
$1.89 19.62%
unlock
2032
$2.50 32.28%
unlock
2033
$2.90 16.00%
unlock

P/E ratio

Current -1.80 62.91%
2027
-3.15 75.33%
unlock
2028
-3.71 17.78%
unlock
2029
5.94 260.11%
unlock
2030
1.34 77.44%
unlock
2031
1.12 16.42%
unlock
2032
0.85 24.11%
unlock
2033
0.73 14.12%
unlock

Current Acasti Pharma Inc. Class A Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
TD Cowen
Locked
➜
Locked
Locked Apr 24 2026
HC Wainwright & Co.
Locked
➜
Locked
Locked Feb 18 2025
Craig-Hallum
Locked
➜
Locked
Locked Sep 26 2024
HC Wainwright & Co.
Locked
➜
Locked
Locked Sep 26 2024
Analyst Rating Date
Locked
TD Cowen:
Locked
➜
Locked
Apr 24 2026
Locked
HC Wainwright & Co.:
Locked
➜
Locked
Feb 18 2025
Locked
Craig-Hallum:
Locked
➜
Locked
Sep 26 2024
Locked
HC Wainwright & Co.:
Locked
➜
Locked
Sep 26 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today